The lawsuit, filed by the Rosen Law Firm, alleges that Aardvark’s registration statement and subsequent public disclosures contained materially false information. According to the complaint, the company failed to disclose that ARD-101 posed greater safety risks than previously represented, leading to an overstatement of the drug's clinical and regulatory prospects. Investors claim these omissions caused financial damages once the true scope of the product's risks surfaced.
Aardvark Therapeutics Investors Face October 13 Lead Plaintiff Deadline
Investors who purchased Aardvark Therapeutics securities between February 13, 2025, and May 14, 2026, face an October 13, 2026, deadline to seek lead plaintiff status in a pending securities fraud lawsuit. The action centers on allegations that the company misled shareholders regarding the safety and commercial viability of its drug candidate, ARD-101.
Those who acquired common stock traceable to the company's February 2025 IPO or purchased securities during the defined class period may be entitled to compensation. While a lawsuit has been initiated, no class has yet been certified. Investors currently have the option to retain their own counsel, remain absent class members, or move the court to serve as a lead representative in the litigation.
Comments (0)
No comments yet. Be the first!